SLXP News 143.24 09/15/2014 10:05:08 Salix Pharmaceuticals (

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Salix Pharmaceuticals (SLXP) 143.24 $SLXP

Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire
PR Newswire - 2 hrs 14 mins ago
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.

Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...

Stocks Drag Lower Despite Data; Conversant Soars On ADS Buyout
at Investor's Business Daily - Fri Sep 12, 9:37AM CDT
Stocks leaned lower out of the starting gate Friday, despite an early raft of strong economic data. The Nasdaq and the S&P 500 each dimmed 0.4%. The Dow Jones industrial average backed down 0.3%. Volume was mild to lower, up 1% on the NYSE and down...

Salix Pharmaceuticals Shares Up 35.6% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Sep 10, 4:44PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 5 months, Salix Pharmaceuticals has returned 35.64% as of today's recent price of $147.94.

After Yesterday's Decline of 3.16%, Salix Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Sep 10, 4:02PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $147.56 to a high of $153.26. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $151.32 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....

Four Stock Spotlight Names Near Buy Points
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
Several Stock Spotlight stocks are near correct buy points and might prove profitable trades if the current uptrend can find more traction. The Stock Spotlight's computer-generated screen highlights stocks with strong earnings, strong sales growth...

Salix, Gilead Among 5 Top Medical Leaders To Watch
at Investor's Business Daily - Fri Sep 05, 4:06PM CDT
Top-performing medical stocks can be a panacea for a depressed portfolio. Today's Tech Leaders - Medical Screen features some heavy hitters in the pharmaceutical field. The maker of gastrointestinal disorder drugs such as Pepcid, Salix...

Off the Charts
at The Street - Fri Sep 05, 10:31AM CDT
9/04/14: YY Inc. (YY) broke out above our consolidation level, triggering our entry price. Look for follow-through tomorrow.

Salix Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.81%
Comtex SmarTrend(R) - Thu Sep 04, 4:26PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $153.79 to a high of $158.16. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $157.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.

45.1% Return Seen to Date on SmarTrend Salix Pharmaceuticals Call (SLXP)
Comtex SmarTrend(R) - Wed Sep 03, 10:56AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 45.12% as of today's recent price of $158.28.

Technical Updates, Upcoming Conferences, Drug Trials, and Acquisition Updates - Research Reports on SL Green, Allstate, HCA Holdings, Alexion and Salix
PR Newswire - Wed Sep 03, 8:15AM CDT
Today, Analysts Review released its research reports regarding SL Green Realty Corp. (NYSE: SLG), The Allstate Corporation (NYSE: ALL), HCA (NYSE: HCA), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6173-100free.

Salix Submits Response to XIFAXAN(R) 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
Business Wire - Tue Sep 02, 6:19AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that on August 29, 2014, it submitted its response to the March 7, 2011, Food and Drug Administration (FDA) Complete Response Letter (CRL) regarding the Company's supplemental New Drug Application (sNDA) for XIFAXAN(R) 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix's response, the FDA will have six months to issue a response.

Uptrend Call Working As Salix Pharmaceuticals Stock Rises 44.2% (SLXP)
Comtex SmarTrend(R) - Wed Aug 27, 9:37AM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 4 months, Salix Pharmaceuticals has returned 44.18% as of today's recent price of $157.25.

Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...

After Big Run, Does Chip Designer NXP Have More Left?
at Investor's Business Daily - Tue Aug 26, 4:27PM CDT
Stock Spotlight has been serving up plenty of strong performers in recent weeks -- not surprising, since the market is in a confirmed uptrend. If the stock market has shown us one thing in recent weeks, it's that breakouts from late-stage bases can...

Pharma Equities Technical Analysis -- Sanofi, AstraZeneca, Novartis, Salix Pharma, and AcelRx Pharma
PR Newswire - Tue Aug 26, 7:50AM CDT
On Monday, August 25, 2014, the NASDAQ Composite ended at 4,557.35, up 0.41%, the Dow Jones Industrial Average finished the day 0.44% higher at 17,076.87, and the S&P 500 closed at 1,997.92, up 0.48%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 732.60, up 0.72%, with the index gaining 7.53% in the previous three months. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free research on these five companies can be accessed at:

Termination of Waiting Period, Appointment, Extension Expiration Date, Technical Update, and Financial Results - Research Reports on Salix, Allergan, Valeant, HCA Holdings and Puma Biotechnology
PR Newswire - Fri Aug 22, 7:50AM CDT
Today, Analysts Review released its research reports regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Allergan, Inc. (NYSE: AGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), HCA Holdings Inc. (NYSE: HCA) and Puma Biotechnology Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5912-100free.

S&P 500 Marks New High As Indexes Hold Gains
at Investor's Business Daily - Thu Aug 21, 3:30PM CDT
Major averages closed modestly higher Thursday after existing-home sales, weekly jobless claims and Philly Fed factory data came in above expectations. The Dow industrials led with a 0.4% gain, while the S&P 500 added 0.3% to a new high. The Nasdaq...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 99

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 446

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Kinross Gold: A Decade of Growth Analysis

Updated Category News Views 173

Investing in Kinross Gold: A Decade of Growth Kinross Gold (NYSE: KGC), an influential player in the mining industry, has showcased a remarkable performance over the past decade. With an impressive annualized return of 28.15% that exceeds market benchmarks by 15.29%, investors have much to consider regarding the potential of this gold mining giant. The Impact of...

Continue Reading
Chagee Holdings Limited Reports Robust Financial Growth in Q2 2025

Updated Category News Views 391

Chagee Holdings Limited Shows Impressive Growth in Q2 2025 Chagee Holdings Limited (NASDAQ: CHA), a prominent player in the premium tea drinks sector, has reported impressive unaudited financial results for the second quarter of the financial year. The company, renowned for its innovative approach to freshly-made tea drinks, has made significant strides as it continues to...

Continue Reading
Recent Notification on Major Holdings of RENEWI PLC

Updated Category News Views 149

Understanding Major Holdings in RENEWI PLC Investors and stakeholders often seek clarity on significant holdings within companies. This not only shapes perceptions but also influences future decisions and strategies. RENEWI PLC has recently documented changes regarding its holdings and the requirements for notifying stakeholders. This disclosure is crucial for those...

Continue Reading
Gold Port Corporation Expands Private Placement Funding

Updated Category News Views 244

Gold Port Corporation Increases Private Placement to Meet Demand Gold Port Corporation (CSE: GPO) is excited to announce an increase in its non-brokered private placement as a response to significant investor interest. Originally set to raise $1,500,000 through the sale of 20,000,000 units at a price of $0.075 per unit, the company is now keen on maximizing this...

Continue Reading
Ensemble Enhances Patient Care with Strategic Partnership

Updated Category News Views 83

Ensemble made headlines by teaming up with Mary Washington Healthcare (MWHC) in a move that was supposed to revolutionize healthcare services. Back then, the talk was all about boosting financial performance and enhancing patient experiences through some fancy technology. Traders kept an eye on this partnership, pondering whether it could be more than just corporate...

Continue Reading